Based on these findings, we suggest that limiting the N-acylation of 1-deoxySA could be a therapeutic approach to improve cell migration and wound healing in patients with HSAN1 and type 2 diabetes mellitus. The gene discussed is SPTLC1; the disease is type 2 diabetes mellitus.